[go: up one dir, main page]

WO2009026053A3 - Inhibitors of iaspp interaction with an iaspp binding partner and methods of use - Google Patents

Inhibitors of iaspp interaction with an iaspp binding partner and methods of use Download PDF

Info

Publication number
WO2009026053A3
WO2009026053A3 PCT/US2008/072918 US2008072918W WO2009026053A3 WO 2009026053 A3 WO2009026053 A3 WO 2009026053A3 US 2008072918 W US2008072918 W US 2008072918W WO 2009026053 A3 WO2009026053 A3 WO 2009026053A3
Authority
WO
WIPO (PCT)
Prior art keywords
iaspp
interaction
inhibitors
methods
binding partner
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/072918
Other languages
French (fr)
Other versions
WO2009026053A2 (en
Inventor
Edith Yvonne Jones
Xin Lu
Christian Siebold
Ross Alexander Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Cancer Research Technology Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Cancer Research Technology Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of WO2009026053A2 publication Critical patent/WO2009026053A2/en
Publication of WO2009026053A3 publication Critical patent/WO2009026053A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides the crystal structure of the iASPP C-terminal protein molecule. The structure is set out in Table 1. The structure may be used in to model the interaction of compounds such as pharmaceuticals with this protein, and to determine the structure of related iASPP C-terminal molecules.
PCT/US2008/072918 2007-08-21 2008-08-12 Inhibitors of iaspp interaction with an iaspp binding partner and methods of use Ceased WO2009026053A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0716322A GB0716322D0 (en) 2007-08-21 2007-08-21 Crystal structure
GB0716322.3 2007-08-21

Publications (2)

Publication Number Publication Date
WO2009026053A2 WO2009026053A2 (en) 2009-02-26
WO2009026053A3 true WO2009026053A3 (en) 2009-07-30

Family

ID=38599037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/072918 Ceased WO2009026053A2 (en) 2007-08-21 2008-08-12 Inhibitors of iaspp interaction with an iaspp binding partner and methods of use

Country Status (2)

Country Link
GB (1) GB0716322D0 (en)
WO (1) WO2009026053A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131019A1 (en) * 2012-03-02 2013-09-06 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031229A2 (en) * 2002-10-07 2004-04-15 Ludwig Institute For Cancer Research P53 binding polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031229A2 (en) * 2002-10-07 2004-04-15 Ludwig Institute For Cancer Research P53 binding polypeptide

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BELL HELEN S ET AL: "A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo", JOURNAL OF CLINICAL INVESTIGATION, vol. 117, no. 4, April 2007 (2007-04-01), pages 1008 - 1018, XP002506964, ISSN: 0021-9738 *
BELL HELEN S ET AL: "iASPP inhibition: increased options in targeting the p53 family for cancer therapy.", CANCER RESEARCH 1 JUL 2008, vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 4959 - 4962, XP002506966, ISSN: 1538-7445 *
BERGAMASCHI D ET AL: "IASPP ONCOPROTEIN IS A KEY INHIBITOR OF P53 CONSERVED FROM WORM TO HUMAN", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 33, no. 2, 1 February 2003 (2003-02-01), pages 162 - 167, XP001180301, ISSN: 1061-4036 *
DELISSE-GATHOYE A-M ET AL: "CLONING PARTIAL SEQUENCE EXPRESSION AND ANTIGENIC ANALYSIS OF THE FILAMENTOUS HEMAGGLUTININ GENE OF BORDETELLA-PERTUSSIS", INFECTION AND IMMUNITY, vol. 58, no. 9, 1990, pages 2895 - 2905, XP002507148, ISSN: 0019-9567 *
GORINA S ET AL: "STRUCTURE OF THE P53 TUMOR SUPPRESSOR BOUND TO THE ANKYRIN AND SH3 DOMAINS OF 53BP2", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 274, no. 5289, 1 January 1996 (1996-01-01), pages 1001 - 1005, XP000907136, ISSN: 0036-8075 *
ROBINSON ET AL: "Biochemical and Structural Studies of ASPP Proteins Reveal Differential Binding to p53, p63, and p73", STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US, vol. 16, no. 2, 12 February 2008 (2008-02-12), pages 259 - 268, XP022475304, ISSN: 0969-2126 *
SLEE ELIZABETH A ET AL: "The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization", ONCOGENE, NATURE PUBLISHING GROUP, GB BASINGSTOKE, HANTS, vol. 23, no. 56, 2 December 2004 (2004-12-02), pages 9007 - 9016, XP002422528, ISSN: 0950-9232 *
YANG J P ET AL: "Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 28 MAY 1999, vol. 274, no. 22, 28 May 1999 (1999-05-28), pages 15662 - 15670, XP002506965, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
GB0716322D0 (en) 2007-10-03
WO2009026053A2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CO6180433A2 (en) LINGO LINK MOLECULES AND PHARMACEUTICAL USE OF THE SAME
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2007117564A3 (en) Clay-binding peptides and methods of use
WO2007100535A3 (en) Oxyntomodulin derivatives
WO2008143666A3 (en) Crystal structures of neuropilin fragments and neuropilin-antibody complexes
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2008106644A3 (en) Treatment of diseases characterized by inflammation
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
PL1893651T3 (en) Solubility of cellulose in ionic liquids with addition of amino bases
WO2009129267A3 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2007115821A3 (en) Organic compounds
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2008063783A3 (en) Biomarkers related to metabolic age and methods using the same
NO20082240L (en) GLP-2 imitators, polypeptides, compositions, methods and applications
WO2009123764A3 (en) Compositions and use of epas1 inhibitors
WO2010115118A3 (en) Methods for preparing and using multichaperone-antigen complexes
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
WO2007100412A3 (en) Methods and compositions related to the modulation of riboswitches
WO2005105842A3 (en) Crystal structure of cytochrome p450 3a4 and uses thereof
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
WO2007103468A3 (en) Use of vx-702 for treating rheumatoid arthritis
MX2007011493A (en) Anti-inflammatory modalities.
WO2004108749A3 (en) Binding peptides: methods for their generation and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08797718

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08797718

Country of ref document: EP

Kind code of ref document: A2